Clinical trial · Interventional
Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism
NCT02127840CI-TRIAL-00014395ISIRAunknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The project is aimed to determine the value of synacthen infusion on the results of adrenal venous sampling in patients examined for primary aldosteronism
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Primary Aldosteronism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Synacthen infusion during adrenal venous sampling | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Synacthen
- description
- Synacthen infusion during adrenal venous sampling
- interventionNames
- Drug: Synacthen infusion during adrenal venous sampling
- type
- NO_INTERVENTION
- label
- Without Synacthen
- description
- Adrenal venous sampling without Synacthen
Primary outcomes (1)
- measure
- To verify whether Synacthen infusion may influence the results of adrenal venous sampling in patients with primary aldosteronism
- timeFrame
- End of clinical examination procedure, i.e. within 4 week after adrenal venous sampling is performed.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Confirmed primary aldosteronism Exclusion Criteria: Inability to undergo unilateral adrenalectomy
References
Publications (0)
Data not yet available
No reference posted for this study.